Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects

被引:48
|
作者
Heuberger, Jules A. A. C. [1 ]
Cohen, Adam F. [1 ,2 ]
机构
[1] Ctr Human Drug Res, Zernikedreef 8, NL-2333 CL Leiden, Netherlands
[2] Leiden Univ, Dept Internal Med, Med Ctr, Leiden, Netherlands
关键词
INCREASES ERYTHROPOIETIN LEVELS; RISK MYELODYSPLASTIC SYNDROMES; ANDROGENIC-ANABOLIC STEROIDS; GROWTH-HORMONE; EXERCISE PERFORMANCE; BODY-COMPOSITION; PHYSICAL PERFORMANCE; ENDURANCE EXERCISE; GLUCOCORTICOID INTAKE; PLASMA TESTOSTERONE;
D O I
10.1007/s40279-018-1014-1
中图分类号
G8 [体育];
学科分类号
04 ; 0403 ;
摘要
The World Anti-Doping Agency is responsible for maintaining a Prohibited List that describes the use of substances and methods that are prohibited for athletes. The list currently contains 23 substance classes, and an important reason for the existence of this list is to prevent unfair competition due to pharmacologically enhanced performance. The aim of this review was to give an overview of the available evidence for performance enhancement of these substance classes. We searched the scientific literature through PubMed for studies and reviews evaluating the effects of substance classes on performance. Findings from double-blind, randomized controlled trials were considered as evidence for (the absence of) effects if they were performed in trained subjects measuring relevant performance outcomes. Only 5 of 23 substance classes show evidence of having the ability to enhance actual sports performance, i.e. anabolic agents, 2-agonists, stimulants, glucocorticoids and -blockers. One additional class, growth hormone, has similar evidence but only in untrained subjects. The observed effects all relate to strength or sprint performance (and accuracy for -blockers); there are no studies showing positive effects on reliable markers of endurance performance. For 11 classes, no well-designed studies are available, and, for the remaining six classes, there is evidence of an absence of a positive effect. In conclusion, for the majority of substance classes, no convincing evidence for performance enhancement is available, while, for the remaining classes, the evidence is based on a total of only 266 subjects from 11 studies.
引用
收藏
页码:525 / 539
页数:15
相关论文
共 50 条
  • [1] Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects
    Jules A. A. C. Heuberger
    Adam F. Cohen
    [J]. Sports Medicine, 2019, 49 : 525 - 539
  • [2] Comment on “Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects”
    Darías Holgado
    Thomas Zandonai
    Daniel Sanabria
    [J]. Sports Medicine, 2019, 49 : 1135 - 1136
  • [3] Comment on "Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects"
    Holgado, Darias
    Zandonai, Thomas
    Sanabria, Daniel
    [J]. SPORTS MEDICINE, 2019, 49 (07) : 1135 - 1136
  • [4] Reply to Holgado et al.: Comment on “Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects”
    Jules A. A. C. Heuberger
    Adam F. Cohen
    [J]. Sports Medicine, 2019, 49 : 1137 - 1137
  • [5] Reply to Holgado et al.: Comment on "Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects"
    Heuberger, Jules A. A. C.
    Cohen, Adam F.
    [J]. SPORTS MEDICINE, 2019, 49 (07) : 1137 - 1137
  • [6] Australian athletes' knowledge of the WADA Prohibited Substances List and performance enhancing substances
    Orr, Rhonda
    Grassmayr, Matthew
    Macniven, Rona
    Grunseit, Anne
    Halaki, Mark
    Bauman, Adrian
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2018, 56 : 40 - 45
  • [7] Performance-Enhancing Substances in Sports: A Review of the Literature
    Momaya, Amit
    Fawal, Marc
    Estes, Reed
    [J]. SPORTS MEDICINE, 2015, 45 (04) : 517 - 531
  • [8] Performance-Enhancing Substances in Sports: A Review of the Literature
    Amit Momaya
    Marc Fawal
    Reed Estes
    [J]. Sports Medicine, 2015, 45 : 517 - 531
  • [10] Use of Performance-Enhancing Substances
    LaBotz, Michele
    Griesemer, Bernard A.
    [J]. PEDIATRICS, 2016, 138 (01)